|
000
| 01975nam 2200301za 4500 |
|---|
| 001 | 9.850877 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107154246 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 180129s2018 onca o f000 0 eng d |
|---|
| 020 | |a9780660247205|z9780660247212 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aNR16-202/2018E-PDF|zNR16-202/2018 |
|---|
| 110 | 2 |aNational Research Council Canada. |
|---|
| 245 | 10|aBlood-brain barrier carriers (L-11085, 11750, 12133, 12596, 12599, 12600) |h[electronic resource]. |
|---|
| 260 | |a[Ottawa] : |bNational Research Council Canada, |c2018. |
|---|
| 300 | |a[2] p. : |bcol. ill. |
|---|
| 500 | |aIssued also in French under title: Transporteurs pour franchir la barrière hémato-encéphalique (L-11085, 11750, 12133, 12596, 12599, 12600). |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"February 2018." |
|---|
| 520 | |a"The blood-brain barrier (BBB) is the principal hurdle in developing drugs for central nervous system (CNS) diseases such as Alzheimer’s, Parkinson’s, brain cancer, epilepsy and others. Composed of tightly adjoined endothelial cells, the BBB actively repels foreign matter from the brain; virtually no biologic molecules are able to cross it to elicit a therapeutic response. To address the need for disease-modifying CNS biologics, the NRC has developed carriers for delivering therapeutics beyond brain barriers. They can be coupled to a wide range of client molecules in order to prevent, diagnose, and treat CNS diseases"--Highlights, p. [1]. |
|---|
| 530 | |aIssued also in print format. |
|---|
| 693 | 4|aDrug carriers (Pharmacy) |
|---|
| 693 | 4|aBlood-brain barrier |
|---|
| 775 | 08|tTransporteurs pour franchir la barrière hémato-encéphalique (L-11085, 11750, 12133, 12596, 12599, 12600) |w(CaOODSP)9.850879 |
|---|
| 776 | 0#|tBlood-brain barrier carriers L-11085, 11750, 12133, 12596, 12599, 12600 |w(CaOODSP)9.850878 |
|---|
| 856 | 40|qPDF|s147 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-202-2018-eng.pdf |
|---|